BIOMEDICAL SCIENCES GRADUATE PROGRAM SPRING 2015
|
|
- Cornelius Stevens
- 5 years ago
- Views:
Transcription
1 THE OHIO STATE UNIVERSITY BIOMEDICAL SCIENCES GRADUATE PROGRAM SPRING 2015 W. Hans Meisen PhD Candidate Improving Oncolytic Viral Therapy for Brain Tumors BRT AM
2 VITA Born Stafford, VA B.S. Biology; University of Virginia M.S. Microbiology; Georgetown University Ph.D, Candidate; Biomedical Sciences; Ohio State University COMMITTEE MEMBERS Dr. Balveen Kaur Dr. Timothy Cripe Dr. Jonathan Godbout Dr. Susheela Tridandapani
3 ABSTRACT Oncolytic viruses [OVs] are an exciting cancer immunotherapy which has received considerable attention in recent years. OVs are viruses designed to specifically destroy cancer cells and promote anti-tumor immune responses. Promising phase 3 clinical trial data in melanoma patients suggests FDA approval for OV therapy may soon be a reality. Despite successes in cancers like melanoma, the efficacy of these viruses in central nervous system [CNS] cancers has been limited. While these viruses have proved safe in early phase clinical trials, durable responses have not been achieved. The unique brain tumor microenvironment and restrictive blood brain barrier make these cancers a therapeutic challenge for researchers and clinicians. The goal of these studies was to develop novel strategies to improve OV therapy for CNS cancers. In part one of this dissertation we examined the therapeutic efficacy of a targeted OV for breast cancer [BC] brain metastases. The 2 year survival rate of patients with this disease is less than 2%. Treatment options for BC brain metastases are limited and there is an unmet need to identify novel therapies for this disease. Brain angiogenesis inhibitor 1 [BAI1] is a G-protein coupled receptor involved in tumor angiogenesis, invasion, phagocytosis, and synaptogenesis. Here, we found BAI1 expression was significantly reduced in BC and higher expression was associated with better patient survival. Nestin is an intermediate filament whose expression is up-regulated in several cancers. We found higher Nestin expression significantly correlated with BC lung and brain metastases. These findings suggested both BAI1 and Nestin could be therapeutic targets for this disease. We then demonstrated the ability of an OV, 34.5ENVE, to target and kill high nestin expressing cells and deliver therapeutic Vstat120 [extracellular fragment of BAI1]. Finally, we demonstrated 34.5ENVE could extend the survival of mice in two models of BC brain metastases.
4 In the context of OV therapy, the immune response is a doubleedged sword. While it has the potential to generate long-term antitumor immune responses, early innate immune responses to viral infection reduce OV replication, tumor destruction, and efficacy. In part two of this dissertation, we characterized the antiviral effects of macrophages and microglia on OV therapy for glioblastoma. Glioblastoma is one of the most common and deadly types of primary brain tumors, and patients diagnosed with these tumors have a median survival of only 15 months. We identified microglia/macrophage secreted tumor necrosis factor α [TNFα] as a major factor which reduces OV replication through the induction of apoptosis in infected tumor cells. We demonstrated that the transient inhibition of TNFα could significantly enhance OV replication and anti-tumor efficacy in vivo. The results of these studies suggest FDA approved TNFα inhibitors may significantly enhance patient outcomes in OV clinical trials for glioblastoma. One of the challenges to creating novel therapeutics, such as OVs, for CNS cancers is developing animal models and non-invasive imaging modalities in which to evaluate them. Live animal imaging is particularly challenging in brain tumor models because the skull significantly limits options for monitoring tumor growth and treatment responses. Bioluminescent imaging [BLI] and magnetic resonance imaging [MRI] are two non-invasive imaging modalities which can significantly enhance intracranial tumor studies. These imaging modalities allow real time measurements of tumor volume, cancer cell viability, and therapeutic responses, but they vary in the information they can provide. In part three of this dissertation we evaluated BLI and MRI in three murine glioblastoma models. We found BLI and MRI output was significantly affected by tumor necrosis, hemorrhaging, tumor depth, extra-cranial growth, and animal positioning. In synthesizing the data from this study, we created a multi-modality imaging paradigm for analyzing changes in tumor growth and biology while reducing cost-prohibitive and time consuming MRI for preclinical brain tumor studies.
5 RECENT ABSTRACTS AND PRESENTATIONS ORAL PRESENTATIONS: 2014 Meisen W.H. Vstat120 tempers the microglia innate inflammatory response to oncolytic viral therapy. 16th Annual Meeting of the Translational Research Cancer Centers Consortium: Immune Suppression and the Tumor Microenvironment, Seven Springs, PA Meisen WH. Vstat120 modulates immune responses to oncolytic viral treatment and enhances efficacy for GBM. The 7th International Meeting On Replicating Oncolytic Virus Therapeutics, Quebec, Canada Meisen W.H. Susceptibility of CNS Breast Cancer Metastases to Oncolytic Viral Therapy. 15th Annual Meeting of the Translational Research Cancer Centers Consortium: Immune Suppression and the Tumor Microenvironment, Seven Springs, PA Meisen W.H. Vstat120 tempers the microglia innate inflammatory response to oncolytic viral therapy. 14th Annual Meeting of the Translational Research Cancer Centers Consortium: Immune Suppression and the Tumor Microenvironment, Seven Springs, PA. POSTER PRESENTATIONS: 2014 Meisen WH, Dubin S, Sizemore S, Mathsyaraja H, Thies K, Lehman NL, Boyer P, Jaime-Ramirez AC, Elder JB, Powell K, Chakravarti A, Ostrowski MC, Kaur B. Susceptibility of CNS Breast Cancer Metastases to Oncolytic Viral Therapy. AACR San Antonio Breast Cancer Symposium. San Antonio, Texas. Poster Presentation Meisen WH, Hardcastle J, Wojton J, Wohleb E, Alvarez- Breckenridge C, Nowiki M, Godbout J, Kaur B. Vstat120 reduces TNFα directed immune responses to oncolytic viral
6 treatment and enhances efficacy for GBM. 17 th Annual Meeting for the American Society of Gene and Cell Therapy, Washington, DC Meisen WH, Hardcastle J, Wojton J, Wohleb E, Alvarez- Breckenridge C, Nowiki M, Godbout J, Kaur B. Vstat120 modulates immune responses to oncolytic viral treatment and enhances efficacy for GBM. The Seventh International Meeting On Replicating Oncolytic Virus Therapeutics, Quebec, Canada Meisen WH, Dubin S, Sizemore S, Mathsyaraja H, Thies K, Lehman NL, Boyer P, Jaime-Ramirez AC, Elder JB, Powell K, Chakravarti A, Ostrowski MC, Kaur B. Susceptibility of CNS Breast Cancer Metastases to Oncolytic Viral Therapy. Translational Research Cancer Centers Consortium. Seven Springs, Pennsylvania. Poster Presentation Meisen WH, Hardcastle J, Wojton J, Wohleb E, Alvarez- Breckenridge C, Nowiki M, Godbout J, Kaur B. Vstat120 tempers the microglia/monocyte innate inflammatory response augmenting oncolytic viral therapy. 17 th Annual Scientific Meeting of the Society for Neuro-Oncology. Washington, DC. Poster Presentation. RECENT PUBLICATIONS REVIEWS/EDITORIALS 1. Meisen WH and Kaur B. How can we trick the immune system into overcoming the detrimental effects of oncolytic viral therapy to treat glioblastoma? Expert Rev Neurother 13(4), (2013).
7 RESEARCH ARTICLES 2. Qin, Y., Meisen, W.H., Hao, Y. & Macara, I.G. Tuba, a Cdc42 GEF, is required for polarized spindle orientation during epithelial cyst formation. The Journal of cell biology 189, (2010). PMID: Wojton J, Chu Z, Mathsyaraja H, Meisen WH, Denton N, Kwon CH, Chow LM, Ostrowski M, Palascak M, Franco R, Bourdeau T, Thornton S, Kaur B, and Qi X. Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma. Molecular Therapy 21(8): (2013). PMID: Racoma IO, Meisen WH, Wang QE, Kaur B, and Wani AA. Thymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cells. PLOS One 8(9) (2013). PMID: Okemoto K, Wagner B, Meisen WH, Haseley A, Kaur B, and Chiocca E.A. STAT3 activation promotes oncolytic HSV1 replication in glioma cells. PLOS One 8(8) (2013). PMID: Okemoto K, Kasai K, Wagner B, Haseley A, Meisen WH, Bolyard C, Mo X, Wehr A, Lehman A, Fernandez S, Kaur B, and Chiocca EA. DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas. Clinical Cancer Research, 19(21): (2013). PMID: Thorne AH, Meisen W.H., Russell LO, Yoo JY, Bolyard CM, Lathia JD, Rich J, Puduvalli VK, Mao H, Yu J, Caligiuri MA, Tridandapani S, Kaur B. Role of CCN1 in macrophage-mediated oncolytic virus clearance. Molecular Therapy. (2014). PMID:
8 8. Van Brocklyn JR, Wojton J, Meisen WH, Kellough DA, Ecsedy JA, Kaur B, and Lehman NL. Aurora-A inhibition offers a novel therapy effective against intracranial glioblastoma. Cancer Research. (2014). PMID: Wojton J, Meisen WH, Jacob NK, Thorne AH, Hardcastle J, Denton N, Chu Z, Dmitrieva N, Marsh R, Van Meir EG, Kwon CH, Chakravarti A, Qi X, Kaur B. SapC-DOPSinduced lysosomal cell death synergizes with TMZ in glioblastoma. Oncotarget. (2014). PMID: Meisen WH, Dubin S, Sizemore ST, Mathsyaraja H, Thies K, Lehman N, Jaime-Ramirez AC, Elder JB, Ostrowski M, Kaur B. Oncolytic Viral Therapy Enhances the Survival of Mice in a Novel Model of Breast Cancer Brain Metastasis. Molecular Cancer Therapeutics. (2014). PMID: [E-published ahead of print]. 11. Meisen WH, Wohleb E, Jaime Ramirez AC, Bolyard C, Yoo JY, Russell L, Hardcastle J, Dubin S, Godbout J, Kaur B. The impact of macrophage and microglia secreted TNFα on oncolytic HSV-1 therapy in the glioblastoma tumor microenvironment. Accepted Clinical Cancer Research Han J, Chu J, Zhang J, Wang Y, Cohen JB, Victor A, Meisen WH, Kim S, Grandi P, Wang Q, He X, Nakano I. Chiocca EA, Glorioso JC, Kaur B, Caliguiri MA, Yu J. Targeting Wild-Type EGFR and Mutant EGFRvIII with CAR-Engineered NK Cells Efficiently Eliminates Glioblastoma and Its Patient-Derived Stem Cells In Vitro and In Vivo. In Revision at Nature Scientific Reports.
9 AWARDS AND HONORS 2014 Ohio State University Presidential Fellowship, Columbus, Ohio Ohio State University Board of Trustees Student Recognition Award, Columbus, Ohio Outstanding Poster Presentation Award, 17 th Annual Meeting for the American Society of Gene and Cell Therapy. Washington, DC Travel Award, The Seventh International Meeting On Replicating Oncolytic Virus Therapeutics. Quebec, Canada Travel Award, 12th Annual OSUWMC (OSU Wexner Medical Center) Trainee Research Day. The Ohio State University, Columbus, OH College of Medicine Systems and Integrative Biology Fellowship, Sponsored by National Institute of General Medical Sciences and the OSU College of Medicine, Columbus, Ohio. FUTURE PLANS I will pursue a post doctoral research position in cancer research.
10 Biomedical Sciences Graduate Program 1170 Graves Hall 333 W. 10 th Avenue Columbus, Ohio 43210
BIOMEDICAL SCIENCES GRADUATE PROGRAM SPRING 2018
THE OHIO STATE UNIVERSITY BIOMEDICAL SCIENCES GRADUATE PROGRAM SPRING 2018 Nicholas Denton PhD Candidate Modulation of tumor associated macrophages enhances oncolytic herpes virotherapy in preclinical
More informationBIOMEDICAL SCIENCES GRADUATE PROGRAM SPRING 2017
THE OHIO STATE UNIVERSITY BIOMEDICAL SCIENCES GRADUATE PROGRAM SPRING 2017 Stephen M Bergin PhD Candidate Activation of Hypothalamic BDNF Modulates Lymphocyte Immunity February 17 th, 2017 Room 105, Biomedical
More informationBIOMEDICAL SCIENCES GRADUATE PROGRAM SUMMER 2013
THE OHIO STATE UNIVERSITY BIOMEDICAL SCIENCES GRADUATE PROGRAM SUMMER 2013 Edward Lloyd Briercheck PhD Candidate Elucidation of the Mechanism by which Phosphatase and Tensin Homologue Deleted on Chromosome
More informationBIOMEDICAL SCIENCES GRADUATE PROGRAM SUMMER 2014
THE OHIO STATE UNIVERSITY BIOMEDICAL SCIENCES GRADUATE PROGRAM SUMMER 2014 Jessica Rose Napolitano PhD Candidate Examination of the role of ZIP8 and cadmium in the development of Chronic Obstructive Pulmonary
More informationBIOMEDICAL SCIENCES GRADUATE PROGRAM SPRING 2018
THE OHIO STATE UNIVERSITY BIOMEDICAL SCIENCES GRADUATE PROGRAM SPRING 2018 Anisley Valenciaga PhD Candidate Cell cycle regulators and transcriptional targeting in Medullary Thyroid Cancer 04/06/18 BRT
More informationBIOMEDICAL SCIENCES GRADUATE PROGRAM AUTUMN 2014
THE OHIO STATE UNIVERSITY BIOMEDICAL SCIENCES GRADUATE PROGRAM AUTUMN 2014 Nathan James Dissinger PhD Candidate Role of HTLV-1 HBZ and HTLV-2 APH-2 in Disease Outcome November 5 th, 2014 84 Veterinary
More informationBIOMEDICAL SCIENCES GRADUATE PROGRAM SPRING 2017
THE OHIO STATE UNIVERSITY BIOMEDICAL SCIENCES GRADUATE PROGRAM SPRING 2017 Grant Foglesong PhD Candidate Lifestyle Improvements Enhance Metabolic Function and Mitigate Breast Cancer Progression March 20
More informationINTEGRATED BIOMEDICAL SCIENCE GRADUATE PROGRAM FALL 2010
THE OHIO STATE UNIVERSITY INTEGRATED BIOMEDICAL SCIENCE GRADUATE PROGRAM FALL 2010 Integrated Biomedical Science Graduate Program 1170 Graves Hall 333 W. 10 th Avenue Columbus, Ohio 43210 Stephanie Cush
More informationImmunotherapy for Malignant Brain Cancer: Overcoming Immune Suppression to Improve the Clinical Experience
Immunotherapy for Malignant Brain Cancer: Overcoming Immune Suppression to Improve the Clinical Experience Derek Wainwright, PhD Assistant Professor Departments of Neurological Surgery, Microbiology-Immunology
More informationPHONE: FAX: EDUCATION
NAME: POSITION: ADDRESS: EMAIL: WEB: Balveen Kaur Associate Professor Department of Neurological surgery Dardinger Laboratory of Neurosciences The Ohio State University 385-D OSUCCC 410 west 12th Avenue
More informationOff-Label Treatments. Clinical Trials for Recurrent GBM UCSF Radiation Oncology Course: Management of Recurrent Disease. Outline
Off-Label Treatments Clinical Trials for Recurrent GBM UCSF Radiation Oncology Course: Management of Recurrent Disease Jennifer Clarke, MD, MPH Assistant Professor Division of Neuro-Oncology Depts of Neurological
More informationIndex. neurosurgery.theclinics.com. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A A Complimentary Trial of an Immunotherapy Vaccine Against Tumor-specific EGFRvIII (ACTIVATE), 90 91 Active immunotherapy, 5 8, 96. See
More informationDurable Responses Observed in IDH1 Wildtype and Mutant Recurrent High Grade Glioma with Toca 511 & Toca FC Treatment
Durable Responses Observed in IDH1 Wildtype and Mutant Recurrent High Grade Glioma with Toca 511 & Toca FC Treatment Cloughesy TF 1, Landolfi J 2, Vogelbaum MA 3, Ostertag D 4, Elder JB 5, Bloomfield S
More informationExploring Immunotherapies: Beyond Checkpoint Inhibitors
Exploring Immunotherapies: Beyond Checkpoint Inhibitors Authored by: Jennifer Dolan Fox, PhD VirtualScopics (Now part of BioTelemetry Research) jennifer_fox@virtualscopics.com +1 585 249 6231 Introduction
More informationOncolytic Immunotherapy: A Local and Systemic Antitumor Approach
Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach Oncolytic immunotherapy Oncolytic immunotherapy the use of a genetically modified virus to attack tumors and induce a systemic immune response
More informationBIOMEDICAL SCIENCES GRADUATE PROGRAM SPRING 2015
THE OHIO STATE UNIVERSITY BIOMEDICAL SCIENCES GRADUATE PROGRAM SPRING 2015 Adam Suhy PhD Candidate Regulation of Cholesteryl Ester Transfer Protein and Expression of Transporters in the Blood Brain Barrier
More informationNovel MOAs and targets for cancer drug development What s hot off the presses?
Novel MOAs and targets for cancer drug development What s hot off the presses? Moderator: Jeremy Goldberg, President, JPG Healthcare LLC Panelists: Robert J Schneider, PhD, Associate Director, NYU Cancer
More informationTumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant
Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be
More informationAnti-tumor Effects of Activated Human Natural Killer Cells in Orthotopic Human Brain Tumor Models
Anti-tumor Effects of Activated Human Natural Killer Cells in Orthotopic Human Brain Tumor Models William Murphy, PhD Depts. of Dermatology and Internal Medicine Neal Goodwin, PhD Jackson Laboratories
More informationDurable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics. Timothy Cloughesy, MD University of California, Los Angeles
Durable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics Timothy Cloughesy, MD University of California, Los Angeles Disclosure 2 FDA Endpoints for the Approval of Cancer
More informationBIT 120. Copy of Cancer/HIV Lecture
BIT 120 Copy of Cancer/HIV Lecture Cancer DEFINITION Any abnormal growth of cells that has malignant potential i.e.. Leukemia Uncontrolled mitosis in WBC Genetic disease caused by an accumulation of mutations
More informationPosters and Presentations
Posters and Presentations June 2017: American Society of Clinical Oncology (ASCO) Annual - Preliminary Correlative Analysis of PD-L1 expression from the SUNRISE Study. View April 2017: American Association
More informationYale University School of Medicine Department of Psychiatry 34 Park Street, New Haven, CT (office)
ERIC S. WOHLEB, PH.D. 1 ERIC S. WOHLEB, PH.D. Department of Psychiatry 34 Park Street, New Haven, CT 06519 eric.wohleb@yale.edu 203-974-7744 (office) POSITIONS: April 2015 Present EDUCATION & TRAINING:
More informationDouglas Jolly Executive VP R&D Tocagen Inc.
REPLICATING RETROVIRUSES FOR MANIPULATION OF THE TUMOR IMMUNE ECOSYSTEM: PRECLINICAL AND CLINICAL OUTCOMES. Douglas Jolly Executive VP R&D Tocagen Inc. PEGS 2018 IT Track Boston May 1 2018 Outline Phase
More informationCELL BIOLOGY - CLUTCH CH CANCER.
!! www.clutchprep.com CONCEPT: OVERVIEW OF CANCER Cancer is a disease which is primarily caused from misregulated cell division, which form There are two types of tumors - Benign tumors remain confined
More information2016 ONCOLYTIC VIRUS IMMUNOTHERAPY Part of CHI s
MEETING REPORT: 2016 ONCOLYTIC VIRUS IMMUNOTHERAPY Part of CHI s www.immuno-oncologysummit.com By Cole Peters and Fares Nigim, M.D. from Mass General Hospital - Harvard Medical School Cambridge Healthtech
More information2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical
More informationIntrinsic cellular defenses against virus infection
Intrinsic cellular defenses against virus infection Detection of virus infection Host cell response to virus infection Interferons: structure and synthesis Induction of antiviral activity Viral defenses
More informationABBVIE VENTURES VISION. Drive strategic returns to AbbVie as a key constituent of overall corporate strategy
ABBVIE VENTURES ABBVIE VENTURES VISION Drive strategic returns to AbbVie as a key constituent of overall corporate strategy Early access to external innovation with a long-term horizon to generate meaningful
More informationOncolytic Virotherapy: Targeting Cancer Stem Cells
Oncolytic Virotherapy: Targeting Cancer Stem Cells Cancer Stem Cells (CSCs) or Cancer Initiating Cells (CICs) A consensus of five defining criteria has been established to affirm the existence of CICs:
More informationDurable Responses Observed in Recurrent High Grade Glioma (rhgg) with Toca 511 & Toca FC Treatment
Durable Responses Observed in Recurrent High Grade Glioma (rhgg) with Toca 511 & Toca FC Treatment Cloughesy TF 1, Landolfi J 2, Vogelbaum MA 3, Ostertag D 4, Elder JB 5, Bloomfield S 2, Carter B 6, Chen
More informationCURRICULUM VITAE. Phone: (614) Lane Road Department of Pathology MR5 Building, Room Charlottesville, VA 22903
CURRICULUM VITAE NAME: AFFILIATION: CITIZENSHIP: HOME ADDRESS: OFFICE ADDRESS: Jordan T. Gladman Postdoctoral Research Associate The University of Virginia Charlottesville, Virginia 22908 Citizen of U.S.A.
More informationImmune surveillance hypothesis (Macfarlane Burnet, 1950s)
TUMOR-IMMUNITÄT A.K. Abbas, A.H. Lichtman, S. Pillai (6th edition, 2007) Cellular and Molecular Immunology Saunders Elsevier Chapter 17, immunity to tumors Immune surveillance hypothesis (Macfarlane Burnet,
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationThe Immune System: The Mind Body Connection. Presented by Margaret Kemeny, Ph.D. Department of Psychiatry, University of California, San Francisco
The Immune System: The Mind Body Connection Presented by Margaret Kemeny, Ph.D. Department of Psychiatry, University of California, San Francisco Psychoneuroimmunology Investigation of the bidirectional
More informationReviewers' comments: Reviewer #1 (Remarks to the Author):
Reviewers' comments: Reviewer #1 (Remarks to the Author): In the manuscript Rational Combination of CXCL11-Expressing Oncolytic Virus and PD-L1 Blockade Works Synergistically to Enhance Therapeutic Efficacy
More informationCURRICULUM VITAE. Keming Yang, MD, MS
CURRICULUM VITAE Keming Yang, MD, MS Department of Epidemiology Richard M. Fairbanks School of Public Health, Indiana University 1050 Wishard Blvd, RG 5129, Indianapolis, IN 46202-2872. Email: kemyang@iu.edu
More informationCurrent and Future Treatment Options for Glioblastoma
Current and Future Treatment Options for Glioblastoma Santosh Kesari, MD, PhD, FANA, FAAN Chair, Department of Translational Neurosciences and Neurotherapeutics John Wayne Cancer Institute & Pacific Neuroscience
More informationMedical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University
Medical Virology Immunology Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University Human blood cells Phases of immune responses Microbe Naïve
More informationRole of Cysteine-rich 61 Protein (CCN1) in Macrophage-mediated Oncolytic Herpes Simplex Virus Clearance
Oncolytics original article Role of Cysteine-rich 6 Protein (CCN) in Macrophage-mediated Oncolytic Herpes Simplex Virus Clearance Amy Haseley Thorne, Walter H Meisen, Luke Russell, Ji Young Yoo, Chelsea
More informationCopyright. Tocagen Inc. Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview
Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview Toca 511, delivers CD prodrug activator gene selectively to cancer cells Regulatory genes Structural RRV genes CD gene Regulatory genes Toca
More informationBookID <BID>_ChapID <CID>_Proof# 1-16/09/2009 Glioblastoma
Glioblastoma Swapan K. Ray Editor Glioblastoma Molecular Mechanisms of Pathogenesis and Current Therapeutic Strategies Editor Swapan K. Ray Department of Pathology, Microbiology, and Immunology University
More informationAmy Lin, Ph.D. November 14, 2018
PD L1 checkpoint blockade using a single chain variable fragment targeting PD L1 delivered by retroviral replicating vector (Toca 521) enhances anti tumor effect in murine cancer models Amy Lin, Ph.D.
More informationImmuno-Oncology: Perspectives on Current Therapies & Future Developments
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-industry-feature/immuno-oncology-perspectives-currenttherapies-future-developments/9502/
More informationAntibody-Drug Conjugates in Glioblastoma Multiforme: Finding Ways Forward
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationImmunotherapy Concept Turned Reality
Authored by: Jennifer Dolan Fox, PhD VirtualScopics Inc. jennifer_fox@virtualscopics.com +1 585 249 6231 Immunotherapy Concept Turned Reality Introduction While using the body s own immune system as a
More informationDelivery Options for Successful Oncolytic Virotherapy Joe Conner, CSO, Virttu Biologics
December 2015 Delivery Options for Successful Oncolytic Virotherapy Joe Conner, CSO, Virttu Biologics Delivery Options for Successful Oncolytic Virotherapy? Intra-tumoral Injection Loco-Regional Infusion
More informationImmune Checkpoints in the Tumor Environment:
Immune Checkpoints in the Tumor Environment: Novel Targets and the Clinical Promise of Combined Immunotherapies Monday, 28 October 2013 07.00 08.00 (AM) Parkside Ballroom B, Convention Centre Level 1 Phosphatidylserine
More informationTreatment of 200 Locally Advanced (Stage III) Pancreatic Adenocarcinoma Patients with Irreversible Electroporation: Safety and Efficacy
The following three articles refer to the same April 2015 ASA presentation, and the same research. But, more data is offered in the third article. Treatment of 200 Locally Advanced (Stage III) Pancreatic
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 27 May 2017 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Challenges in immunooncology
More informationOsimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study
Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study Abstract 9002 Yang JC, Kim DW, Kim SW, Cho BC, Lee JS, Ye X, Yin X, Yang
More informationOncolytic virus strategy
Oncolytic viruses Oncolytic virus strategy normal tumor NO replication replication survival lysis Oncolytic virus strategy Mechanisms of tumor selectivity of several, some of them naturally, oncolytic
More informationCurriculum Vitae. Chun-Yu Lin, M.S.
Curriculum Vitae Chun-Yu Lin, M.S. Cognition & Neuroimaging Lab 1503 E. University Blvd. Tucson, AZ 85721 Phone: 520-406-4417 E-mail: cylin@u.arizona.edu Website: http://www.u.arizona.edu/~cylin EDUCATION
More informationOhio State Urology Update. New fellowship offering Research focus on pediatric UTIs Men s Sexual Health adds new service
Ohio State Urology Update New fellowship offering Research focus on pediatric UTIs Men s Sexual Health adds new service 3,185 SURGICAL CASES 2 FELLOWS Ohio State Urology by the Numbers OFFICE AND OUTPATIENT
More informationBasis of Immunology and
Basis of Immunology and Immunophysiopathology of Infectious Diseases Jointly organized by Institut Pasteur in Ho Chi Minh City and Institut Pasteur with kind support from ANRS & Université Pierre et Marie
More informationCorey J. Wallach, MD The Anderson Orthopaedic Clinic 2445 Army Navy Drive Arlington, VA
Corey J. Wallach, MD The Anderson Orthopaedic Clinic 2445 Army Navy Drive Arlington, VA 22206 703-769-8424 Current: Orthopedic Spine Surgeon, The Anderson Orthopaedic Clinic 2007- Present Medical Director,
More informationIntravenous Delivery of Toca 511 in Patients With High Grade Glioma Results in Quantifiable Expression of Cytosine Deaminase in Tumor Tissue
Intravenous Delivery of Toca 511 in Patients With High Grade Glioma Results in Quantifiable Expression of Cytosine Deaminase in Tumor Tissue Tobias Walbert, 1 Daniela Bota, 2 Michael A Vogelbaum, 3 Steven
More informationTITLE: Selective Oncolytic Therapy for Hypoxic Breast Cancer Cells. CONTRACTING ORGANIZATION: Ordway Research Institute Albany, New York 12208
AD Award Number: W81XWH-06-1-0586 TITLE: Selective Oncolytic Therapy for Hypoxic Breast Cancer Cells PRINCIPAL INVESTIGATOR: Michael T. Fasullo, Ph.D. CONTRACTING ORGANIZATION: Ordway Research Institute
More informationIt s s Always Something!
It s s Always Something! New Approaches in Brain Tumor Treatment Virginia Stark-Vance, M.D. When Something Is a Brain Tumor Brain tumors aren t rare: there are over 100,000/yr Most originate as other cancers
More informationEvidence for Systemic Effects Moves PV-10 Toward Further Clinical Trials
PV-10 Moves Forward-1 Evidence for Systemic Effects Moves PV-10 Toward Further Clinical Trials At the same time that current research projects are solidifying and reinforcing the evidence for PV-10 s systemic
More informationInnate immunity. Abul K. Abbas University of California San Francisco. FOCiS
1 Innate immunity Abul K. Abbas University of California San Francisco FOCiS 2 Lecture outline Components of innate immunity Recognition of microbes and dead cells Toll Like Receptors NOD Like Receptors/Inflammasome
More informationCancer changes lives, but so do you. How YOU are changing the cancer story
Cancer changes lives, but so do you. How YOU are changing the cancer story Research and Clinical Trials Report to Donors 2017 You ve given the gift of HOPE Hope is at the heart of cancer research. Hope
More informationThis is an author produced version of Future clinical potential of oncolytic virotherapy for pediatric CNS tumors.
This is an author produced version of Future clinical potential of oncolytic virotherapy for pediatric CNS tumors. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/87766/ Article:
More informationCytokine Arrays Reveal Black Ops Tactics of Tumor-induced Immunosuppression
Cytokine Arrays Reveal Black Ops Tactics of Tumor-induced Immunosuppression Jarad J Wilson, Ph.D. Technical Support & Marketing Specialist Ruo-Pan Huang, MD, Ph.D. Founder and CEO What are Antibody Arrays?
More informationCancer arises from the mutation of a normal gene. A factor which brings about a mutation is called a mutagen.
Cancer Single cells divide by mitosis to form many cells. This cells undergo physical and chemical changes in order to perform specific functions. (we say the cells have Differentiated) in this way we
More information08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells
Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines
More informationORYX Translational Medicine. Dr. Bernard Huber / CEO
ORYX Translational Medicine Dr. Bernard Huber / CEO BIO International Convention June 2016 ORYX Overview ORYX GmbH & Co. KG (ORYX) is a privately held company for translational oncology founded in 2007
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationSection Lectures: Immunology/Virology Time: 9:00 am 10:00 am LRC 105 A & B
Section Director: Cliff Bellone, Ph.D. Office: Doisy Hall - R 405 Phone: 577-8449 E-Mail: bellonec@slu.edu Lecturers: James Swierkosz, Ph.D. Office: Medical School Rm. 412 Phone: 577-8430 E-Mail: swierkoszje@slu.edu
More informationBIOMEDICAL SCIENCES GRADUATE PROGRAM SUMMER 2014
THE OHIO STATE UNIVERSITY BIOMEDICAL SCIENCES GRADUATE PROGRAM SUMMER 2014 Elizabeth Stofko Barrie PhD Candidate Genetic Factors Regulating Expression of Dopaminergic Genes July 15 th, 2014 159 DHLRI 1:00
More informationThe 150 most important questions in cancer research and clinical oncology series: questions 6 14
DOI 10.1186/s40880-017-0200-0 Chinese Journal of Cancer EDITORIAL Open Access The 150 most important questions in cancer research and clinical oncology series: questions 6 14 Edited by Chinese Journal
More information-738 proteins were found only in the ME subjects proteins were only found in PTLS samples proteins were only found in the normal controls.
RECENT RESEARCH Currently there is much exciting research being published including the Schutzer et al. study that compared cerebrospinal fluid proteomes to differentiate ME and Post Treatment Lyme Syndrome
More informationBioWorld s. PARTNER in FOCUS: Tactical Therapeutics. REUTERS/Srdjan Zivulovic AN ADVERTISING SERVICE FROM BIOWORLD
BioWorld s PARTNER in FOCUS: Tactical Therapeutics REUTERS/Srdjan Zivulovic AN ADVERTISING SERVICE FROM BIOWORLD breakthroughs in cancer therapy: new and improved cto shows promise One thing is certain
More informationThe Next Generation of Immunotherapy Platforms. 36 th Annual J.P. Morgan Healthcare Conference January 2018
The Next Generation of Immunotherapy Platforms 36 th Annual J.P. Morgan Healthcare Conference January 2018 Forward-Looking Statements This presentation contains certain forward-looking information about
More informationOncolytic Viruses as a Potential Approach to Eliminate the HIV Reservoir
Oncolytic Viruses as a Potential Approach to Eliminate the HIV Reservoir Costiniuk CT, Côté SC, Al-Ghazawi FM, Carrasco-Medina L,Young CD, & Angel JB University of Ottawa, November 12 th, 2012 HIV Reservoirs
More informationNicholas Szerlip, MD Department of Neurosurgery Wayne State University Karmanos Cancer Institute
Nicholas Szerlip, MD Department of Neurosurgery Wayne State University Karmanos Cancer Institute Many different names (Heregulin, Aria) Found when investigating ligands that activated HER2 (it actually
More informationInvolvement of TLR4/STAT3 signaling in the antimelanoma effects of atractylenolide II. Fu Xiuqiong
Involvement of TLR4/STAT3 signaling in the antimelanoma effects of atractylenolide II Fu Xiuqiong Melanoma fact Skin cancers Skin cancer deaths 2.3% 75% Melanoma Non-melanoma skin cancers ----American
More informationCYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION
CYTOKINE RECEPTORS AND SIGNAL TRANSDUCTION What is Cytokine? Secreted popypeptide (protein) involved in cell-to-cell signaling. Acts in paracrine or autocrine fashion through specific cellular receptors.
More informationAn update on your support of the Kaplan Cancer Research Fund Swedish Cancer Institute
An update on your support of the Swedish Cancer Institute At Swedish, we re committed to offering our patients the newest, most innovative cancer treatment available. Through your support of the at the
More informationOncolytic viruses for cancer treatment
Oncolytic viruses for cancer treatment Interdisciplinary Technical Journal Club: Special Series on Laboratory Animal Science Dr. Katrin Frauenknecht Institute of Neuropathology University Hospital Zurich
More informationEarly Embryonic Development
Early Embryonic Development Maternal effect gene products set the stage by controlling the expression of the first embryonic genes. 1. Transcription factors 2. Receptors 3. Regulatory proteins Maternal
More informationAnti-infectious Immunity
Anti-infectious Immunity innate immunity barrier structures Secretory molecules Phagocytes NK cells Anatomical barriers 1. Skin and mucosa barrier 2.hemo-Spinal Fluid barrier 3. placental barrier Phagocytic
More informationNon-invasive Neurosurgery using MR guided Focused Ultrasound
Non-invasive Neurosurgery using MR guided Focused Ultrasound About InSightec Founded in 1999, headquarters Haifa, Israel US offices in Dallas, Texas Asian offices in Beijing, China, and Tokyo, Japan Develop
More informationConcept of oncolytic virotherapyclinical
Concept of oncolytic virotherapyclinical implementation Simona Donina A. Kirchenstein Institute of Microbiology and Virology, Riga Stradiņš University Riga East University Hospital 4.04.2014. Timeline
More informationCancer and Gene Alterations - 1
Cancer and Gene Alterations - 1 Cancer and Gene Alteration As we know, cancer is a disease of unregulated cell growth. Although we looked at some of the features of cancer when we discussed mitosis checkpoints,
More informationA holistic approach to targeting breast cancer part II: Micronutrient synergy. Presented by: Dr. Neha Shanker DRRI
A holistic approach to targeting breast cancer part II: Micronutrient synergy Presented by: Dr. Neha Shanker DRRI Overview of the previous webinar In the last presentation we talked about: Increase in
More informationDr. Bernard Huber CEO. Bio-Europe
Dr. Bernard Huber CEO Bio-Europe 2015 1 ORYX Overview ORYX GmbH & Co. KG (ORYX) is a privately held company for translational oncology founded in 2007 and located in Baldham/Munich, Germany ORYX bridges
More informationMeasles virus vaccine induces oncolysis of tumor cells and activates immune responses.
Measles virus vaccine induces oncolysis of tumor cells and activates immune responses. Marc Grégoire*, J.-F. Fonteneau, N. Boisgerault, J.-B. Guillerme and F. Tangy. * INSERM, Nantes, F-44, France. Pasteur
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationA Phase I Dose Escalation Study of Intratumoral Herpes Simplex Virus 1 Mutant rrp450 in Patients with Refractory Sarcoma or Neuroblastoma
A Phase I Dose Escalation Study of Intratumoral Herpes Simplex Virus 1 Mutant rrp450 in Patients with Refractory Sarcoma or Neuroblastoma Timothy P. Cripe, M.D., Ph.D. Associate Professor Division of Hematology/Oncology
More informationThe Immune System. These are classified as the Innate and Adaptive Immune Responses. Innate Immunity
The Immune System Biological mechanisms that defend an organism must be 1. triggered by a stimulus upon injury or pathogen attack 2. able to counteract the injury or invasion 3. able to recognise foreign
More informationBL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES. Overview and Mechanism of Action Dr.
BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES Overview and Mechanism of Action Dr. Leah Klapper, CSO 88 BL-8040: Novel CXCR4 Antagonist For Hematological Cancers Indications:
More informationBIMM134 The Biology of Cancer SPRING 2015
BIMM134 The Biology of Cancer SPRING 2015 Lectures: CENTR 214 Tuesdays/Thursdays, March 31 June 4 8:00 9:20 AM Instructor: Eric Bennett, Ph.D. email - e1bennett@ucsd.edu Office Hours: Tuesday and Thursday
More informationImmuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The
More informationAntigen Presentation to T lymphocytes
Antigen Presentation to T lymphocytes Immunology 441 Lectures 6 & 7 Chapter 6 October 10 & 12, 2016 Jessica Hamerman jhamerman@benaroyaresearch.org Office hours by arrangement Antibodies and T cell receptors
More informationHuman Immune Response. Part 1: innate immunity
Human Immune Response Part 1: innate immunity Our bodies are under constant attack from pathogens A pathogen is an organism that can cause disease Pathogens include: Bacteria Viruses Protists Fungi 6.3.1
More informationInnate Immunity. Bởi: OpenStaxCollege
Innate Immunity Bởi: OpenStaxCollege The vertebrate, including human, immune system is a complex multilayered system for defending against external and internal threats to the integrity of the body. The
More informationClinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: PA.CP.MP.145
Clinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: PA.CP.MP.145 Effective Date: 01/18 Last Review Date: 04/18 Coding Implications Revision Log Description Electric tumor treating
More informationEDUCATION AND PROFESSIONAL EXPERIENCE. M.B.A. University of Findlay, Ohio, Major: Management and Quality Assurance.
Curriculum Vitae SANDRA J. REED Assistant Director, Research Methodology Center College of Education and Human Ecology, The Ohio State University 177C Arps Hall, 1945 North High Street Columbus, OH 43210
More information